Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary D Bowers

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Bioanalysis|February 19, 2013
Metabolite structure analysis by high-resolution MS: supporting drug-development studiesDavid S Wagner, Jill L Pirhalla, Gary D Bowers
The Journal of Pharmacology and Experimental Therapeutics|June 12, 2015
Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of UnityFang Xie, Alice B Ke, Gary D Bowers, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 19, 2014
The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeysLee Moss, David Wagner, Eri Kanaoka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2011
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicityStephen Castellino, Michael O'Mara, Kevin Koch, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 DiabetesRebecca J Hodge, Jiang Lin, Lakshmi S Vasist Johnson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2015
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolamMelinda J Reese, Gary D Bowers, Joan E Humphreys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 2, 2012
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studiesJames F Sigafoos, Gary D Bowers, Stephen Castellino, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2013
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibioticGary D Bowers, David Tenero, Parul Patel, et al.
Journal of Medicinal Chemistry|May 30, 2003
Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeysEric E Boros, Vicente Samano, John A Ray, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Bioanalysis|February 19, 2013
Metabolite structure analysis by high-resolution MS: supporting drug-development studiesDavid S Wagner, Jill L Pirhalla, Gary D Bowers
The Journal of Pharmacology and Experimental Therapeutics|June 12, 2015
Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of UnityFang Xie, Alice B Ke, Gary D Bowers, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 19, 2014
The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeysLee Moss, David Wagner, Eri Kanaoka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2011
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicityStephen Castellino, Michael O'Mara, Kevin Koch, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 DiabetesRebecca J Hodge, Jiang Lin, Lakshmi S Vasist Johnson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2015
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolamMelinda J Reese, Gary D Bowers, Joan E Humphreys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 2, 2012
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studiesJames F Sigafoos, Gary D Bowers, Stephen Castellino, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2013
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibioticGary D Bowers, David Tenero, Parul Patel, et al.
Journal of Medicinal Chemistry|May 30, 2003
Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeysEric E Boros, Vicente Samano, John A Ray, et al.
Pageof 1